{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:52:01Z","timestamp":1783705921876,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T00:00:00Z","timestamp":1558915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00392-019-01490-2","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T18:04:15Z","timestamp":1558980255000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["When and how do patients with cardiac amyloidosis die?"],"prefix":"10.1007","volume":"109","author":[{"given":"F.","family":"Escher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Senoner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Doerler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Zaruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Messner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mussner-Seeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ensinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kroiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Ulmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schneiderbauer-Porod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Poelzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,27]]},"reference":[{"key":"1490_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","volume":"29","author":"P Elliott","year":"2008","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, Dubourg O, Kuhl U, Maisch B, McKenna WJ, Monserrat L, Pankuweit S, Rapezzi C, Seferovic P, Tavazzi L, Keren A (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29:270\u2013276","journal-title":"Eur Heart J"},{"key":"1490_CR2","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","volume":"120","author":"C Rapezzi","year":"2009","unstructured":"Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120:1203\u20131212","journal-title":"Circulation"},{"key":"1490_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/bjh.12286","volume":"161","author":"JH Pinney","year":"2013","unstructured":"Pinney JH, Smith CJ, Taube JB, Lachmann HJ, Venner CP, Gibbs SD, Dungu J, Banypersad SM, Wechalekar AD, Whelan CJ, Hawkins PN, Gillmore JD (2013) Systemic amyloidosis in England: an epidemiological study. Br J Haematol 161:525\u2013532","journal-title":"Br J Haematol"},{"key":"1490_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1080\/13506120802676948","volume":"16","author":"E Dardiotis","year":"2009","unstructured":"Dardiotis E, Koutsou P, Papanicolaou EZ, Vonta I, Kladi A, Vassilopoulos D, Hadjigeorgiou G, Christodoulou K, Kyriakides T (2009) Epidemiological, clinical and genetic study of familial amyloidotic polyneuropathy in Cyprus. Amyloid 16:32\u201337","journal-title":"Amyloid"},{"key":"1490_CR5","doi-asserted-by":"publisher","first-page":"1826","DOI":"10.1093\/eurheartj\/ehv583","volume":"37","author":"T Damy","year":"2016","unstructured":"Damy T, Costes B, Hagege AA, Donal E, Eicher JC, Slama M, Guellich A, Rappeneau S, Gueffet JP, Logeart D, Plante-Bordeneuve V, Bouvaist H, Huttin O, Mulak G, Dubois-Rande JL, Goossens M, Canoui-Poitrine F, Buxbaum JN (2016) Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J 37:1826\u20131834","journal-title":"Eur Heart J"},{"key":"1490_CR6","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","volume":"2","author":"SF Mohammed","year":"2014","unstructured":"Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2:113\u2013122","journal-title":"JACC Heart Fail"},{"key":"1490_CR7","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585\u20132594","journal-title":"Eur Heart J"},{"key":"1490_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ, Merlini G (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66:2451\u20132466","journal-title":"J Am Coll Cardiol"},{"key":"1490_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","volume":"133","author":"LH Connors","year":"2016","unstructured":"Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC (2016) Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study. Circulation 133:282\u2013290","journal-title":"Circulation"},{"key":"1490_CR10","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1093\/eurheartj\/ehw033","volume":"37","author":"A Galat","year":"2016","unstructured":"Galat A, Guellich A, Bodez D, Slama M, Dijos M, Zeitoun DM, Milleron O, Attias D, Dubois-Rande JL, Mohty D, Audureau E, Teiger E, Rosso J, Monin JL, Damy T (2016) Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J 37:3525\u20133531","journal-title":"Eur Heart J"},{"key":"1490_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, Singleton A, Kiuru-Enari S, Paetau A, Tienari PJ, Myllykangas L (2008) Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 40:232\u2013239","journal-title":"Ann Med"},{"key":"1490_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1161\/CIRCULATIONAHA.111.078915","volume":"126","author":"FL Ruberg","year":"2012","unstructured":"Ruberg FL, Berk JL (2012) Transthyretin (TTR) cardiac amyloidosis. Circulation 126:1286\u20131300","journal-title":"Circulation"},{"key":"1490_CR13","doi-asserted-by":"publisher","first-page":"e002877","DOI":"10.1161\/JAHA.115.002877","volume":"5","author":"BW Sperry","year":"2016","unstructured":"Sperry BW, Vranian MN, Hachamovitch R, Joshi H, Ikram A, Phelan D, Hanna M (2016) Subtype-specific interactions and prognosis in cardiac amyloidosis. J Am Heart Assoc 5:e002877","journal-title":"J Am Heart Assoc"},{"key":"1490_CR14","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","volume":"165","author":"B Ng","year":"2005","unstructured":"Ng B, Connors LH, Davidoff R, Skinner M, Falk RH (2005) Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. Arch Intern Med 165:1425\u20131429","journal-title":"Arch Intern Med"},{"key":"1490_CR15","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","volume":"387","author":"AD Wechalekar","year":"2016","unstructured":"Wechalekar AD, Gillmore JD, Hawkins PN (2016) Systemic amyloidosis. Lancet 387:2641\u20132654","journal-title":"Lancet"},{"key":"1490_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1161\/CIRCULATIONAHA.110.010447","volume":"124","author":"RH Falk","year":"2011","unstructured":"Falk RH (2011) Cardiac amyloidosis: a treatable disease, often overlooked. Circulation 124:1079\u20131085","journal-title":"Circulation"},{"key":"1490_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1093\/eurheartj\/ehu506","volume":"36","author":"RH Sayed","year":"2015","unstructured":"Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD (2015) A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 36:1098\u20131105","journal-title":"Eur Heart J"},{"key":"1490_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79:319\u2013328","journal-title":"Am J Hematol"},{"key":"1490_CR19","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00392-017-1092-3","volume":"106","author":"K Dahlem","year":"2017","unstructured":"Dahlem K, Michels G, Kobe C, Bunck AC, Ten Freyhaus H, Pfister R (2017) Diagnosis of cardiac transthyretin amyloidosis based on multimodality imaging. Clin Res Cardiol 106:471\u2013473","journal-title":"Clin Res Cardiol"},{"key":"1490_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s00392-016-1067-9","volume":"106","author":"M Fritschka","year":"2017","unstructured":"Fritschka M, Schlegl M, Borges A, Werner M, Gebker R, Pieske B, Kelle S (2017) Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis. Clin Res Cardiol 106:311\u2013316","journal-title":"Clin Res Cardiol"},{"key":"1490_CR21","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, Witzig TE, Lust JA, Rajkumar SV, Fonseca R, Zeldenrust SR, McGregor CG, Jaffe AS (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 22:3751\u20133757","journal-title":"J Clin Oncol"},{"key":"1490_CR22","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68:1014\u20131020","journal-title":"J Am Coll Cardiol"},{"key":"1490_CR23","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1093\/oxfordjournals.eurheartj.a015074","volume":"17","author":"R Narang","year":"1996","unstructured":"Narang R, Cleland JG, Erhardt L, Ball SG, Coats AJ, Cowley AJ, Dargie HJ, Hall AS, Hampton JR, Poole-Wilson PA (1996) Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J 17:1390\u20131403","journal-title":"Eur Heart J"},{"key":"1490_CR24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/eurjhf\/hfs113","volume":"14","author":"P Rickenbacher","year":"2012","unstructured":"Rickenbacher P, Pfisterer M, Burkard T, Kiowski W, Follath F, Burckhardt D, Schindler R, Brunner-La Rocca HP, Investigators T-C (2012) Why and how do elderly patients with heart failure die? Insights from the TIME-CHF study. Eur J Heart Fail 14:1218\u20131229","journal-title":"Eur J Heart Fail"},{"key":"1490_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016","journal-title":"N Engl J Med"},{"key":"1490_CR26","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","volume":"69","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Patel RB, Michel A, Shah SJ, Senni M, Gheorghiade M, Butler J (2017) Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol 69:556\u2013569","journal-title":"J Am Coll Cardiol"},{"key":"1490_CR27","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00392-017-1167-1","volume":"107","author":"FAD Siepen","year":"2018","unstructured":"Siepen FAD, Bauer R, Voss A, Hein S, Aurich M, Riffel J, Mereles D, Rocken C, Buss SJ, Katus HA, Kristen AV (2018) Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol 107:158\u2013169","journal-title":"Clin Res Cardiol"},{"key":"1490_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00392-016-1058-x","volume":"106","author":"D Mohty","year":"2017","unstructured":"Mohty D, Pradel S, Magne J, Fadel B, Boulogne C, Petitalot V, Raboukhi S, Darodes N, Damy T, Aboyans V, Jaccard A (2017) Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis. Clin Res Cardiol 106:331\u2013340","journal-title":"Clin Res Cardiol"},{"key":"1490_CR29","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","volume":"94","author":"DA Brenner","year":"2004","unstructured":"Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 94:1008\u20131010","journal-title":"Circ Res"},{"key":"1490_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.hrthm.2007.10.016","volume":"5","author":"AV Kristen","year":"2008","unstructured":"Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5:235\u2013240","journal-title":"Heart Rhythm"},{"key":"1490_CR31","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jce.12123","volume":"24","author":"G Lin","year":"2013","unstructured":"Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24:793\u2013798","journal-title":"J Cardiovasc Electrophysiol"},{"key":"1490_CR32","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1161\/CIRCULATIONAHA.107.697763","volume":"116","author":"D Feng","year":"2007","unstructured":"Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, Hughes DA, Lust JA, Jaffe AS, Gertz MA, Klarich KW (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116:2420\u20132426","journal-title":"Circulation"},{"key":"1490_CR33","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0002-9149(83)90084-X","volume":"52","author":"WC Roberts","year":"1983","unstructured":"Roberts WC, Waller BF (1983) Cardiac amyloidosis causing cardiac dysfunction: analysis of 54 necropsy patients. Am J Cardiol 52:137\u2013146","journal-title":"Am J Cardiol"},{"key":"1490_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH 3rd, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321","journal-title":"N Engl J Med"},{"key":"1490_CR35","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331","journal-title":"N Engl J Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-019-01490-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-019-01490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T23:11:56Z","timestamp":1590448316000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-019-01490-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,27]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["1490"],"URL":"https:\/\/doi.org\/10.1007\/s00392-019-01490-2","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,27]]},"assertion":[{"value":"11 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Poelzl G has received speaker honoraria from Pfizer and AKCEA Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}